drugset / Trial / NCT02897115
A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
Phase 4
Terminated
22 enrolled
AbbVie
Hannover Medical School · collabIST GmbH, Germany · collabImprovement by Movement GmbH, Germany · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A study comparing a treat-to-target (T2T) intense treatment approach with routine treatment (Standard of Care \[SOC\]) in reducing disease activity in participants with axial spondyloarthritis (axSpA).
Timeline
- Start
- 2016-09-12
- Primary completion
- 2017-12-21
- Completion
- 2017-12-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |